These tools will no longer be maintained as of December 31, 2024. Archived website can be found here. PubMed4Hh GitHub repository can be found here. Contact NLM Customer Service if you have questions.


BIOMARKERS

Molecular Biopsy of Human Tumors

- a resource for Precision Medicine *

142 related articles for article (PubMed ID: 8740842)

  • 21. Epidermal growth factor receptor and HER-2/neu status by immunohistochemistry and fluorescence in situ hybridization in adenocarcinomas of the biliary tree and gallbladder.
    Shafizadeh N; Grenert JP; Sahai V; Kakar S
    Hum Pathol; 2010 Apr; 41(4):485-92. PubMed ID: 20040392
    [TBL] [Abstract][Full Text] [Related]  

  • 22. Liver fluke-associated and sporadic cholangiocarcinoma: an immunohistochemical study of bile duct, peribiliary gland and tumour cell phenotypes.
    Hughes NR; Pairojkul C; Royce SG; Clouston A; Bhathal PS
    J Clin Pathol; 2006 Oct; 59(10):1073-8. PubMed ID: 16679351
    [TBL] [Abstract][Full Text] [Related]  

  • 23. Protein expression and genetic alterations of p53 and ras in intrahepatic cholangiocarcinoma.
    Furubo S; Harada K; Shimonishi T; Katayanagi K; Tsui W; Nakanuma Y
    Histopathology; 1999 Sep; 35(3):230-40. PubMed ID: 10469215
    [TBL] [Abstract][Full Text] [Related]  

  • 24. Biliary dysplasia, cell proliferation and nuclear DNA-fragmentation in primary sclerosing cholangitis with and without cholangiocarcinoma.
    Bergquist A; Glaumann H; Stål P; Wang GS; Broomé U
    J Intern Med; 2001 Jan; 249(1):69-75. PubMed ID: 11168786
    [TBL] [Abstract][Full Text] [Related]  

  • 25. Invasive papillary carcinomas of the extrahepatic bile ducts: a clinicopathologic and immunohistochemical study of 13 cases.
    Hoang MP; Murakata LA; Katabi N; Henson DE; Albores-Saavedra J
    Mod Pathol; 2002 Dec; 15(12):1251-8. PubMed ID: 12481004
    [TBL] [Abstract][Full Text] [Related]  

  • 26. Expression of the GLUT1 glucose transporter and p53 in carcinomas of the pancreatobiliary tract.
    Sung JY; Kim GY; Lim SJ; Park YK; Kim YW
    Pathol Res Pract; 2010 Jan; 206(1):24-9. PubMed ID: 19819644
    [TBL] [Abstract][Full Text] [Related]  

  • 27. Expression and clinical significance of cell cycle regulatory proteins in gallbladder and extrahepatic bile duct cancer.
    Kim WB; Han HJ; Lee HJ; Park SS; Song TJ; Kim HK; Suh SO; Kim YC; Choi SY
    Ann Surg Oncol; 2009 Jan; 16(1):23-34. PubMed ID: 18979138
    [TBL] [Abstract][Full Text] [Related]  

  • 28. Cytokeratin profile relates to histological subtypes and intrahepatic location of intrahepatic cholangiocarcinoma and primary sites of metastatic adenocarcinoma of liver.
    Shimonishi T; Miyazaki K; Nakanuma Y
    Histopathology; 2000 Jul; 37(1):55-63. PubMed ID: 10931219
    [TBL] [Abstract][Full Text] [Related]  

  • 29. Cholangiocarcinoma in primary sclerosing cholangitis: K-ras mutations and Tp53 dysfunction are implicated in the neoplastic development.
    Boberg KM; Schrumpf E; Bergquist A; Broomé U; Pares A; Remotti H; Schjölberg A; Spurkland A; Clausen OP
    J Hepatol; 2000 Mar; 32(3):374-80. PubMed ID: 10735605
    [TBL] [Abstract][Full Text] [Related]  

  • 30. CD56 expression aids in the differential diagnosis of cholangiocarcinomas and benign cholangiocellular lesions.
    Gütgemann I; Haas S; Berg JP; Zhou H; Büttner R; Fischer HP
    Virchows Arch; 2006 Apr; 448(4):407-11. PubMed ID: 16411132
    [TBL] [Abstract][Full Text] [Related]  

  • 31. TP53 mutations and mdm2 protein overexpression in cholangiocarcinomas.
    Della Torre G; Pasquini G; Pilotti S; Alasio L; Civelli E; Cozzi G; Milella M; Salvetti M; Pierotti MA; Severini A
    Diagn Mol Pathol; 2000 Mar; 9(1):41-6. PubMed ID: 10718212
    [TBL] [Abstract][Full Text] [Related]  

  • 32. Dyskerin expression in human fetal, adult and neoplastic intrahepatic bile ducts: correlations with cholangiocarcinoma aggressiveness.
    Vasuri F; Rocchi L; Degiovanni A; Giunchi F; Brandi G; Treré D; Montanaro L; D'Errico-Grigioni A
    Histopathology; 2015 Jan; 66(2):244-51. PubMed ID: 25367684
    [TBL] [Abstract][Full Text] [Related]  

  • 33. [Result of p53, ki-67 protein expression in cholangiocarcinoma with in situ hybridization and immunohistochemistry methods].
    Wang X; Zhang J; Chen J
    Zhongguo Yi Xue Ke Xue Yuan Xue Bao; 2000 Feb; 22(1):57-60. PubMed ID: 12903495
    [TBL] [Abstract][Full Text] [Related]  

  • 34. TTF-1 and Napsin-A are expressed in a subset of cholangiocarcinomas arising from the gallbladder and hepatic ducts: continued caveats for utilization of immunohistochemistry panels.
    Surrey LF; Frank R; Zhang PJ; Furth EE
    Am J Surg Pathol; 2014 Feb; 38(2):224-7. PubMed ID: 24418856
    [TBL] [Abstract][Full Text] [Related]  

  • 35. Differential expression of the anterior gradient protein-2 is a conserved feature during morphogenesis and carcinogenesis of the biliary tree.
    Lepreux S; Bioulac-Sage P; Chevet E
    Liver Int; 2011 Mar; 31(3):322-8. PubMed ID: 21281432
    [TBL] [Abstract][Full Text] [Related]  

  • 36. Expression of cytokeratin 7 and 20 in pathological conditions of the bile tract.
    Cabibi D; Licata A; Barresi E; Craxì A; Aragona F
    Pathol Res Pract; 2003; 199(2):65-70. PubMed ID: 12747467
    [TBL] [Abstract][Full Text] [Related]  

  • 37. Expression of c-erbB-2 proto-oncogene in extrahepatic cholangiocarcinoma and its clinical significance.
    Zheng J; Zhu YM
    Hepatobiliary Pancreat Dis Int; 2007 Aug; 6(4):412-5. PubMed ID: 17690040
    [TBL] [Abstract][Full Text] [Related]  

  • 38. DNA image analysis study of lesions of the gallbladder and biliary system.
    Brunt EM; Kraemer BB
    Liver Transpl Surg; 1996 Jul; 2(4):284-9. PubMed ID: 9346662
    [TBL] [Abstract][Full Text] [Related]  

  • 39. KRAS and GNAS mutations and p53 overexpression in biliary intraepithelial neoplasia and intrahepatic cholangiocarcinomas.
    Hsu M; Sasaki M; Igarashi S; Sato Y; Nakanuma Y
    Cancer; 2013 May; 119(9):1669-74. PubMed ID: 23335286
    [TBL] [Abstract][Full Text] [Related]  

  • 40. Differential cell cycle-regulatory protein expression in biliary tract adenocarcinoma: correlation with anatomic site, pathologic variables, and clinical outcome.
    Jarnagin WR; Klimstra DS; Hezel M; Gonen M; Fong Y; Roggin K; Cymes K; DeMatteo RP; D'Angelica M; Blumgart LH; Singh B
    J Clin Oncol; 2006 Mar; 24(7):1152-60. PubMed ID: 16505435
    [TBL] [Abstract][Full Text] [Related]  

    [Previous]   [Next]    [New Search]
    of 8.